About Alexion
Alexion is a Healthcare company based in Zurich (Switzerland) founded in 1992, and was acquired by Astrazeneca in December 2020. It operates as a therapies for rare and devastating diseases are developed by Alexion. Alexion has raised $8 million across 12 funding rounds from investors including Astrazeneca, Permira and HHS. The company has 2 employees. Alexion has completed 8 acquisitions, including Achillion, Enobia Pharma and LogicBio. Its chief executive is Ludwig Hantson. Its website alexion.com draws about 82 thousand monthly visits. Its Indian entity Alexion Business Services Private Limited reported revenue of ₹92.4 Lakh. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its competitors include Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Alexion was founded in 1992 and is based in Zurich, Switzerland. Focus is placed on developing treatments for rare diseases affecting hematology, nephrology, neurology, metabolic, and cardiology areas. Soliris, a terminal complement inhibitor, is utilized for myasthenia gravis management, and Ultomiris addresses hemolytic uremic syndrome. Operations center on pharmaceutical innovation for underserved patient populations in these medical fields.
- Headquarters Zurich, Switzerland
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website alexion.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Astrazeneca (Dec 2020)
- Legal Name Alexion Business Services Private Limited
- Date of Incorporation 03 Jun, 2011
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹92.4 Lakh
FY 2024 · -73% YoY
- Net Profit₹4 Lakh
FY 2024 · 4% margin
- EBITDA₹5.5 Lakh
FY 2024 · 6% margin
- Total Equity Funding$8M (USD)
in 12 rounds
- Latest Funding Round$3.61B (USD), Debt – Conventional
Jun 2018
- InvestorsAstrazeneca
& 7 more
- Employee Count2
- Investments & AcquisitionsAchillion
& 7 more
- Acquired byAstrazeneca
(Dec 2020)
Associated legal entities of Alexion
Alexion operates through Alexion Business Services Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Alexion Business Services Private Limited CIN U74120MH2011PTC218281 | Active | 03 Jun 2011 | Mumbai, Maharashtra | ₹0.9 Cr | 2 | 3 | View details |
Apps and channels of Alexion
its YouTube channel Alexion Pharmaceuticals US has 233 subscribers and 30 videos.
Videos from Alexion
The most watched videos on Alexion's YouTube channel, Alexion Pharmaceuticals US (233 subscribers). Click a video to play it here.
More on Alexion Pharmaceuticals US.
Funding Insights of Alexion
Alexion has successfully raised a total of $8M across 12 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $3.61 billion completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8M
- Total Rounds 12
- Last Round Debt – Conventional — $3.61B
- First Round $8M
(Jun 1993)
- Investors Count 7
Latest 10 of 12 funding rounds of Alexion with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2018 | $3.61B | Debt – Conventional | – | – | – |
| Jun 2016 | $32.32M | Post-IPO | – | – | |
| Jan 2014 | $25M | Post-IPO | – | – | – |
| Jun 2011 | $1.2M | Grant | – | – | |
| Jun 2011 | $1.2M | Grant | – | – | |
| Aug 2010 | $50.11M | Post-IPO | – | – | – |
| Apr 2010 | $300,000 | Grant | – | – | |
| Mar 2010 | $300,000 | Grant | – | – | |
| Jan 2005 | $125M | Debt – Convertible | – | – | – |
| Mar 1998 | $8.8M | Post-IPO | – | – |
8 investors in total: 8 institutional.
Investors in Alexion
Alexion has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Permira and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in Asia and Europe | 1993 | bbbiotech.ch | Schaffhausen, Switzerland | |
Investments are made in technology, consumer, healthcare, and service sectors. | 1985 | permira.com | London, United Kingdom | |
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | – | ctinnovations.com | - | |
- | – | legalandgeneralgroup.com | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Diversified asset management services are offered globally by Invesco. | – | invesco.com | Atlanta, United States | |
Wealth management firm | 1932 | alleninvestments.com | Lakeland, United States | |
Pharmaceutical and biologics products are developed and distributed worldwide. | 1913 | astrazeneca.com | Cambridge, United Kingdom |
Investor details for Alexion
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Alexion Business Services Private Limited (Alexion)
Alexion Business Services Private Limited is the primary company behind Alexion. The board of Alexion Business Services Private Limited currently have 3 directors; the longest-serving is Michael Ira Kenneth Elloian, appointed in 2018. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Michael Ira Kenneth Elloian DIN 08203437 | Director | 20 Aug 2018 | 8 yrs 2 mo | Alexion Business Services Private Limited |
| Gautam Jamnadas Thakker DIN 08150321 | Director | 07 Jun 2021 | 5 yrs 4 mo | Alexion Business Services Private Limited |
| Mohmmed Rafik Anwar Ali Shekh DIN 07776977 | Alternate Director | 10 Jun 2021 | 5 yrs 4 mo | Alexion Business Services Private Limited |
People of Alexion
171 people are tracked at Alexion (111 in leadership, 7 in board & advisors, 53 in team); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Joseph Madri | Director | Leadership |
Ludwig Hantson | CEO | Leadership |
Brian Gosper | Associate Director, Sales Operations, Pnh, Hematology And Nephrology Business Unit | Leadership |
Cole Allen | Director, US Strategic Account Lead | Leadership |
Mary-Sheila Leese | Vice President, Patient Services & Strategy | Leadership |
Kevin Siska | Sr. Regional Sales Director, Nf1 PN | Leadership |
Lisa Lavorgna | Director, Patient Services Reporting & Analytics | Leadership |
Mark Hill | Director, US Strategic Account Lead | Leadership |
Faraz Lutfi | Head Of Finance - ANZ & China | Leadership |
Adam Pool | IDN Director, Strategic Account Lead | Leadership |
Sean Christie | Chief Financial and Administration Officer | Leadership |
Marc Dunoyer | Chief Executive Officer | Leadership |
Sarah Marshall | VP, Head of Human Resources | Leadership |
Matthew L. Keesecker | Regional Sales Director - Neurology | Leadership |
Wei Shao | Associate Director, Strategy And Business Development | Leadership |
Toby Freyman | Vice President Of Business Development | Leadership |
Suliya Maimaitiming Madani | Executive Director | Leadership |
Cho Yoonjoo | Representative Director, Alexion Pharma Korea Llc. | Leadership |
Michael Gregersen | Finance Business Partner, Hematology & Nephrology | Leadership |
Sofia Pacheco | Associate Director, Strategy & Business Development | Leadership |
151 more people are available in the full profile.
Complete people profiles for Alexion
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Alexion
Figures of Alexion Business Services Private Limited, the primary company behind Alexion, for FY 2024. Revenue was ₹92.4 Lakh (-73% year on year). Net profit was ₹4 Lakh (4% margin). EBITDA was ₹5.5 Lakh (6% margin). Revenue has grown at a compounded annual rate of -32% over three years and -29% over five years.
- ₹92.4 LakhRevenue · FY 2024 · -73% YoY
- ₹4 LakhNet profit · 4% margin
- ₹5.5 LakhEBITDA · 6% margin
- ₹80 LakhPaid-up capital
- 2Employees (provident fund records)
- -32%Revenue CAGR, 3 years
- -29%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Alexion Business Services Private Limited are on its company page.
Detailed financial statements for Alexion
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alexion
Alexion has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Achillion, Enobia Pharma and LogicBio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Viral vectors are developed for genetic and infectious disease treatments. | logicbio.com | Lexington, United States | 2013 | Oct 2022 | $68M | |
Therapeutics for cardiovascular and autoimmune diseases are developed. | portola.com | San Francisco, United States | 2003 | May 2020 | $1.6B | |
Treatments for Hepatitis C and complement-mediated diseases are developed. | achillion.com | New Haven, United States | 1998 | Oct 2019 | $930M | |
IgG-mediated autoimmune diseases are treated via Fc receptor-targeting antibodies. | syntimmune.com | New York, United States | 2013 | Sep 2018 | $400M | |
De-coppering agents for Wilson disease treatment are developed. | wilsontherapeutics.com | Stockholm, Sweden | 2012 | Apr 2018 | $855M | |
Enzyme replacement therapies for rare diseases are developed. | synageva.com | Lexington, United States | 1996 | May 2015 | $8.4B | |
Therapies for genetic metabolic bone disorders are developed. | enobia.com | Quebec, Canada | 1997 | Dec 2011 | $1.1B | |
Protein therapeutics for inflammatory diseases | taligentherapeutics.com | Cambridge, United States | 2004 | Jan 2011 | $111M |
Complete acquisition details for Alexion
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Alexion
13 dated milestones of Alexion across 30 years, from founding to its latest funding, stage changes and deals.
- Founded Alexion is founded.
- Funding First funding round of $8.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Taligen Therapeutics.
- Acquisition Acquires Enobia Pharma.
- Acquisition Acquires Synageva.
- Acquisition Acquires Wilson Therapeutics.
- Funding Latest funding round, Debt – Conventional, of $3.6B.
- Acquisition Acquires Syntimmune.
- Acquisition Acquires Achillion.
- Acquisition Acquires Portola Pharma.
- Exit Acquired by Astrazeneca.
- Acquisition Acquires LogicBio.
Competitors of Alexion
Alexion has 9 listed competitors in our database, 9 of them funded. They include Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| argenx.com | 2008 | Ghent, Belgium | $61.9M | 355 | Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | |
| macrogenics.com | 2000 | Rockville, United States | $126.02M | 339 | A biopharmaceutical company focused on cancer therapeutics development. |
Detailed competitors of Alexion
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Alexion
The website of Alexion (alexion.com) receives about 81.8K visits a month and ranks #498,312 among all websites worldwide, #493 in Biotechnology and Pharmaceuticals.
- Monthly visits81.8K
▲ 49.1% vs previous month
- Unique visitors26.6K
per month
- Global rank#498,312
among all websites
- Category rank#493
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit3.4
- Average visit2 min 33 sec
- DevicesDesktop 54% · Mobile 46%
Websites whose visitors overlap most with Alexion. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| takedaoncology.com | 100% | 14.3K | #1,943,946 | View details | |
| servier.us | 100% | – | #2,050,491 | View details | |
| karyopharm.com | 99% | 11.8K | #3,094,808 | View details | |
| amylyx.com | 96% | 14.1K | #1,731,185 | View details | |
| praxismedicines.com | 93% | 35.6K | #1,244,570 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 25 similar websites and full traffic analytics for Alexion
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 25 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
10 companies that operate in the same segment as Alexion (Rare Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | 2013 | Basel, Basel-stadt, Switzerland | USD 127 M | USD 37.31 M | 393 | |
Gene therapies for rare diseases are developed to treat patients. | 2020 | Columbus, Ohio, United States | USD 250 M | – | – | |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | 2015 | Cambridge, Massachusetts, United States | USD 114.67 M | – | 45 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. | 2019 | Menlo Park, California, United States | USD 90 M | USD 175.11 M | 427 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alexion
Complete news archive for Alexion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alexion
Alexion was founded in 1992 and raised its 1st funding round 1 year after it was founded.
Alexion is headquartered in Zurich, Switzerland.
Ludwig Hantson is the current CEO of Alexion.
Alexion is a funded company, having raised a total of $8M across 12 funding rounds to date. The company's 1st funding round was a Post-IPO of $8.8M, raised on Jun 1993.
Alexion has 2 employees.
The primary company behind Alexion, Alexion Business Services Private Limited, reported revenue of ₹92.4 Lakh for FY 2024, down 73% year on year.
Alexion was founded in 1992 and is based in Zurich, Switzerland. Focus is placed on developing treatments for rare diseases affecting hematology, nephrology, neurology, metabolic, and cardiology areas. Soliris, a terminal complement inhibitor, is utilized for myasthenia gravis management, and Ultomiris addresses hemolytic uremic syndrome. Operations center on pharmaceutical innovation for underserved patient populations in these medical fields.
Alexion's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Alexion has made 8 acquisitions, including Achillion, Enobia Pharma, and LogicBio.
Alexion has 8 investors. Key investors include Astrazeneca, Permira, HHS, Allen & Company, and BB Biotech.
Alexion operates through Alexion Business Services Private Limited.
Yes. Alexion was acquired by Astrazeneca in December 2020.